Ginsberg GM - Search Results

1

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Péchevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board. Beutels P, et al. Among authors: ginsberg gm. Pharmacoeconomics. 2002;20(1):1-7. doi: 10.2165/00019053-200220010-00001. Pharmacoeconomics. 2002. PMID: 11817988 Review.

2

Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Ginsberg G, Lowe S. Ginsberg G, et al. Pharmacoeconomics. 2002;20(6):367-87. doi: 10.2165/00019053-200220060-00002. Pharmacoeconomics. 2002. PMID: 12052096 Review.

3

Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Ginsberg G, Shani S, Lev B. Ginsberg G, et al. Pharmacoeconomics. 1998 Feb;13(2):231-41. doi: 10.2165/00019053-199813020-00006. Pharmacoeconomics. 1998. PMID: 10178649

4

Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Ginsberg GM, Berger S, Shouval D. Ginsberg GM, et al. Bull World Health Organ. 1992;70(6):757-67. Bull World Health Organ. 1992. PMID: 1486673 Free PMC article.

5

Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.

Ginsberg GM, Lev B. Ginsberg GM, et al. Pharmacoeconomics. 1997 Nov;12(5):578-84. doi: 10.2165/00019053-199712050-00008. Pharmacoeconomics. 1997. PMID: 10174324

6

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Ginsberg GM, Shouval D. Ginsberg GM, et al. J Epidemiol Community Health. 1992 Dec;46(6):587-94. doi: 10.1136/jech.46.6.587. J Epidemiol Community Health. 1992. PMID: 1494073 Free PMC article.

7

Generalizability of cost-utility analyses across countries and settings.

Ginsberg GM. Ginsberg GM. Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):845-52. doi: 10.1016/j.bpg.2013.08.017. Epub 2013 Sep 26. Best Pract Res Clin Gastroenterol. 2013. PMID: 24182605 Review.

8

Cost-utility analysis of treating out of hospital cardiac arrests in Jerusalem.

Ginsberg GM, Kark JD, Einav S. Ginsberg GM, et al. Resuscitation. 2015 Jan;86:54-61. doi: 10.1016/j.resuscitation.2014.10.024. Epub 2014 Nov 10. Resuscitation. 2015. PMID: 25447040

9

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.

Ginsberg GM, Somekh E, Schlesinger Y. Ginsberg GM, et al. Isr J Health Policy Res. 2018 Dec 17;7(1):63. doi: 10.1186/s13584-018-0258-4. Isr J Health Policy Res. 2018. PMID: 30554570 Free PMC article.

10

Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Ginsberg GM, Block C, Stein-Zamir C. Ginsberg GM, et al. Int J Public Health. 2016 Jul;61(6):683-692. doi: 10.1007/s00038-016-0821-0. Epub 2016 Apr 22. Int J Public Health. 2016. PMID: 27105884

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page